A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

• CpG has the potential to stimulate the immune system

• this study will evaluate the safety of CpG given sub-q or IV

• purpose is to measure biological changes in CLL cells after receiving CpG

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Iowa
• Collaborators: Mayo Clinic; National Cancer Institute (NCI); Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of CLL

• CLL previously treated

• Hemoglobin >/= 10

• Platelets >/= 50,000

• Neutrophils >= 1,000 -

Exclusion Criteria:

• patients with brain mets

• patients with autoimmune disease

• patients on corticosteroids or immunosuppressants

• patients with uncontrolled intercurrent illness

• pregnant women

• HIV patients receiving combination anti-retroviral therapy